Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
Crossref DOI link: https://doi.org/10.1007/s40262-014-0184-8
Published Online: 2014-09-23
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schipani, Alessandro
Back, David
Owen, Andrew
Davies, Gerry
Khoo, Saye
Siccardi, Marco
Text and Data Mining valid from 2014-09-23
Version of Record valid from 2014-09-23
Article History
First Online: 23 September 2014
Free to read: This content has been made available to all.